Literature DB >> 19549755

Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice.

Xiao Wang1, Maurice R G O'Gorman, Heng-Fu Bu, Viola Koti, Xiu-Li Zuo, Xiao-Di Tan.   

Abstract

Probiotic nutrients have shown promise in therapy for the treatment of gastrointestinal inflammation, infection, and atopic disease. Intestinal dendritic cells (DC) play a critical role in shaping the intestinal immune response. In this study, we tested the effect of a probiotic preparation (VSL#3) on DC distribution and phenotypes within the intestinal mucosa using a lineage depletion-based flow cytometric analysis. In naïve C57BL/10J mice, intestinal mucosal DC were composed of plasmacytoid DC (pDC) and myeloid DC (mDC). The pDC were the dominant form in lamina propria and Peyer's patches, whereas mDC were the prevailing type in the mesenteric lymph nodes. Additional characterization of pDC and mDC with flow cytometry revealed that they expressed heterogeneous phenotypes in the intestinal mucosa. In mice gavaged with the probiotic VSL#3 for 7 d, the proportion of pDC within the lamina propria was >60% lower, whereas the pDC subset in the mesenteric lymph nodes was more than 200% greater than in sham-treated controls (P < 0.01). Within pDC, the proportion of functionally unique CX3CR1(+) DC was greater than in controls in both the lamina propria and the Peyer's patches (P < 0.01). In contrast to pDC, the mDC number was greater than in controls in all intestinal lymphoid tissue compartments in VSL#3-treated mice (P < 0.01). In conclusion, this study suggests that phenotypically and functionally distinct DC subsets are localized to specific lymphoid tissues within the intestinal mucosa and that the VSL#3 probiotic nutritional supplement alters the distribution of the DC subsets within the intestinal mucosa. These changes may be important in the alteration of mucosal immunity following probiotic VSL#3 therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19549755      PMCID: PMC2709306          DOI: 10.3945/jn.109.109934

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  43 in total

1.  CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance.

Authors:  Jan Hendrik Niess; Stephan Brand; Xiubin Gu; Limor Landsman; Steffen Jung; Beth A McCormick; Jatin M Vyas; Marianne Boes; Hidde L Ploegh; James G Fox; Dan R Littman; Hans-Christian Reinecker
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

2.  Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization.

Authors:  Mansour Mohamadzadeh; Scott Olson; Warren V Kalina; Gordon Ruthel; Gretchen L Demmin; Kelly L Warfield; Sina Bavari; Todd R Klaenhammer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

3.  VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Authors:  Rodrigo Bibiloni; Richard N Fedorak; Gerald W Tannock; Karen L Madsen; Paolo Gionchetti; Massimo Campieri; Claudio De Simone; R Balfour Sartor
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

4.  Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes.

Authors:  D Vremec; K Shortman
Journal:  J Immunol       Date:  1997-07-15       Impact factor: 5.422

Review 5.  Oral tolerance and its relation to food hypersensitivities.

Authors:  Mirna Chehade; Lloyd Mayer
Journal:  J Allergy Clin Immunol       Date:  2005-01       Impact factor: 10.793

6.  Modulation of human dendritic cell phenotype and function by probiotic bacteria.

Authors:  A L Hart; K Lammers; P Brigidi; B Vitali; F Rizzello; P Gionchetti; M Campieri; M A Kamm; S C Knight; A J Stagg
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

7.  Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice.

Authors:  Lindsy M Hengesbach; Kathleen A Hoag
Journal:  J Nutr       Date:  2004-10       Impact factor: 4.798

8.  1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype.

Authors:  Lajos Széles; Gábor Keresztes; Dániel Töröcsik; Zoltán Balajthy; László Krenács; Szilárd Póliska; Andreas Steinmeyer; Ulrich Zuegel; Monika Pruenster; Antal Rot; László Nagy
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

9.  CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo.

Authors:  Gabrielle T Belz; Ken Shortman; Michael J Bevan; William R Heath
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

10.  CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo.

Authors:  R Maldonado-López; T De Smedt; P Michel; J Godfroid; B Pajak; C Heirman; K Thielemans; O Leo; J Urbain; M Moser
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  7 in total

1.  Toll-like receptor 2-mediated peptidoglycan uptake by immature intestinal epithelial cells from apical side and exosome-associated transcellular transcytosis.

Authors:  Heng-Fu Bu; Xiao Wang; Yi Tang; Viola Koti; Xiao-Di Tan
Journal:  J Cell Physiol       Date:  2010-03       Impact factor: 6.384

2.  Lactobacillus reuteri strains reduce incidence and severity of experimental necrotizing enterocolitis via modulation of TLR4 and NF-κB signaling in the intestine.

Authors:  Yuying Liu; Nicole Y Fatheree; Nisha Mangalat; Jon Marc Rhoads
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-12-29       Impact factor: 4.052

3.  Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis.

Authors:  Joshua M Uronis; Janelle C Arthur; Temitope Keku; Anthony Fodor; Ian M Carroll; Myrella L Cruz; Caroline B Appleyard; Christian Jobin
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

Review 4.  Probiotics: progress toward novel therapies for intestinal diseases.

Authors:  Fang Yan; David Brent Polk
Journal:  Curr Opin Gastroenterol       Date:  2010-03       Impact factor: 3.287

5.  Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer.

Authors:  Caroline B Appleyard; Myrella L Cruz; Angel A Isidro; Janelle C Arthur; Christian Jobin; Claudio De Simone
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-09-08       Impact factor: 4.052

6.  Lactobacillus paracasei reduces intestinal inflammation in adoptive transfer mouse model of experimental colitis.

Authors:  Manuel Oliveira; Nabil Bosco; Genevieve Perruisseau; Jeanne Nicolas; Iris Segura-Roggero; Stéphane Duboux; Muriel Briand; Stéphanie Blum; Jalil Benyacoub
Journal:  Clin Dev Immunol       Date:  2011-07-25

7.  Enhancement of Oral Tolerance Induction in DO11.10 Mice by Lactobacillus gasseri OLL2809 via Increase of Effector Regulatory T Cells.

Authors:  Ayako Aoki-Yoshida; Kiyoshi Yamada; Satoshi Hachimura; Toshihiro Sashihara; Shuji Ikegami; Makoto Shimizu; Mamoru Totsuka
Journal:  PLoS One       Date:  2016-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.